We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-17.8%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.58B
AUM Growth
-$1.09B
Cap. Flow
+$290M
Cap. Flow %
6.34%
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$158M
2
NTRA icon
Natera
NTRA
+$78.7M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$62.7M
4
ANTX icon
AN2 Therapeutics
ANTX
+$55.6M
5
CTKB icon
Cytek Biosciences
CTKB
+$51M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$125M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$61.3M
3
ZGNX
Zogenix, Inc.
ZGNX
+$54.2M
4
CCCC icon
C4 Therapeutics
CCCC
+$44.4M
5
TGTX icon
TG Therapeutics
TGTX
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 98.82%
2 Financials 0.96%
3 Miscellaneous 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FLACU
76
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$9.99M 0.22%
1,000,000
– –
IOBT
77
DELISTED
IO Biotech
IOBT
$9.85M 0.21%
1,857,755
– –
KLRS
78
Kalaris Therapeutics
KLRS
$76.2M
$9.72M 0.21%
+62,632
New +$12.5M
ARYE
79
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$9.71M 0.21%
1,000,000
– –
PYXS icon
80
Pyxis Oncology
PYXS
$278M
$9.22M 0.2%
2,282,173
– –
ATXS
81
DELISTED
Astria Therapeutics
ATXS
$8.47M 0.18%
1,262,193
– –
FVAM
82
DELISTED
5:01 Acquisition Corp
FVAM
$7.39M 0.16%
750,000
– –
BDTX icon
83
Black Diamond Therapeutics
BDTX
$113M
$7.17M 0.16%
2,589,904
– –
VERV
84
DELISTED
Verve Therapeutics
VERV
$7.08M 0.15%
310,284
– –
ORTX
85
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$6.9M 0.15%
969,479
– –
ENTX icon
86
Entera Bio
ENTX
$495M
$6.75M 0.15%
2,353,000
– –
OBIO icon
87
Orchestra BioMed
OBIO
$363M
$6.19M 0.14%
625,000
– –
LRMR icon
88
Larimar Therapeutics
LRMR
$406M
$5.19M 0.11%
1,281,860
-52,750
-4% -$345K
HLTH
89
DELISTED
Cue Health Inc. Common Stock
HLTH
$4.84M 0.11%
750,000
– –
PHAS
90
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$3.76M 0.08%
2,850,000
– –
CGEM icon
91
Cullinan Oncology
CGEM
$1.32B
$3.67M 0.08%
350,000
– –
TCRX icon
92
TScan Therapeutics
TCRX
$21.8M
$2.86M 0.06%
1,021,764
-233,553
-19% -$1.01M
BMEA icon
93
Biomea Fusion
BMEA
$130M
$2.23M 0.05%
500,000
– –
OLMA icon
94
Olema Pharmaceuticals
OLMA
$856M
$2.15M 0.05%
504,505
-1,645,899
-77% -$9.07M
CVRX icon
95
CVRx
CVRX
$79.9M
$1.65M 0.04%
275,000
– –
CMPX icon
96
Compass Therapeutics
CMPX
$333M
$730K 0.02%
532,958
-1,316,560
-71% -$2.72M
BOLT icon
97
Bolt Biotherapeutics
BOLT
$7.76M
– –
-118,916
Closed -$11.7M
CCCC icon
98
C4 Therapeutics
CCCC
$422M
– –
-1,377,569
Closed -$44.4M
COGT icon
99
Cogent Biosciences
COGT
$5.68B
– –
-1,025,641
Closed -$8.8M
IMA
100
ImageneBio Inc
IMA
$55.8M
– –
-62,500
Closed -$9.4M
1 2 3
4
5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, RA Capital Management held 107 positions worth $4.58B, down 19% from $5.67B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management deployed $290M of net new capital in Q1 2022, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was Biogen: 727,024 shares worth $153M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Novavax, an estimated $125M trimmed.

  • RA Capital Management's largest Q1 2022 buy was Biogen: 727,024 shares worth $153M.
  • RA Capital Management added most to Cytek Biosciences in Q1 2022, an estimated $51M increase.
  • RA Capital Management's biggest Q1 2022 reduction was Novavax, cutting an estimated $125M.
  • RA Capital Management fully exited Phathom Pharmaceuticals in Q1 2022, selling an estimated $61.3M.
  • RA Capital Management's ten largest holdings make up 45% of its $4.58B portfolio in Q1 2022.
  • RA Capital Management opened 10 new positions and closed 11 in Q1 2022.
  • RA Capital Management's portfolio value fell 19% quarter-over-quarter to $4.58B.

Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.